在乳腺癌局部精准治疗中的新进展：联合免疫治疗未来可期

doi:10.19401/j.cnki.1007-3639.2022.08.004

中国癌症杂志 ›› 2022, Vol. 32 ›› Issue (8): 698-704.doi: 10.19401/j.cnki.1007-3639.2022.08.004

在乳腺癌局部精准治疗中的新进展：联合免疫治疗未来可期

周文斌()(), 谢晖, 丁强, 王水()()

南京医科大学第一附属医院乳腺外科,江苏南京,210029

收稿日期:2022-06-12 修回日期:2022-07-09 出版日期:2022-08-30 发布日期:2022-09-19
通信作者: 王水 E-mail:zhouwenbin@njmu.edu.cn;shwang@njmu.edu.cn
作者简介:周文斌（ORCID: 0000-0003-1220-6797）,副主任医师,E-mail: zhouwenbin@njmu.edu.cn。
王水,主任医师,教授,博士研究生导师,中国农工民主党江苏省委副主任委员,全国政协委员。现任江苏省妇幼保健院院长,江苏省人民医院副院长,江苏省乳腺疾病诊疗中心主任;中华医学会外科学分会内分泌乳腺外科学组委员,中国抗癌协会乳腺癌专业委员会委员,中国妇幼保健协会乳腺保健专业委员会主任委员,江苏省中西医结合学会副会长,江苏省中西医学会外科学分会主任委员,江苏省海外联谊会理事,江苏省质量协会副会长。现为国家自然科学基金、卫健委和教育部科研项目评审专家。江苏省135重点医学人才,江苏省六大人才高峰项目重点人才,333工程中青年学科带头人。从事乳腺疾病诊疗30余年,在乳腺癌早期诊断、保乳治疗、乳腺癌前哨淋巴结活检、难治性乳腺癌的综合治疗、乳腺疾病微创物理治疗、乳房再造等方面具有较高水平。主持国家和省级科研课题15项。主编医学著作3部。获得国家级教学成果奖1项、教育部科技成果奖1项、江苏省科技进步二等奖及三等奖各1 项。

New research progress of microwave ablation in the local precise treatment of early-stage breast cancer: the prospect of combined immunotherapy is promising

ZHOU Wenbin()(), XIE Hui, DING Qiang, WANG Shui()()

Department of Breast Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China

Received:2022-06-12 Revised:2022-07-09 Published:2022-08-30 Online:2022-09-19
Contact: WANG Shui E-mail:zhouwenbin@njmu.edu.cn;shwang@njmu.edu.cn

摘要/Abstract

摘要：

乳腺癌是女性最常见的恶性肿瘤,早期乳腺癌治疗以手术为主。目前,早期乳腺癌的诊治已取得了显著进展,但仍需要创新的方法来减少创伤和改善预后。随着乳腺癌治疗手段创新性研究的深入,乳房和腋窝的非手术治疗成为早期乳腺癌治疗的研究热点。微波消融作为一种微创的精准局部治疗方式,具有消融迅速、操作方式简易、术后并发症较少等特点,目前已尝试用于治疗早期乳腺癌,获得了较好的临床效果。此外,有研究报道,早期乳腺癌经微波消融可调节肿瘤免疫微环境,激发体内抗原特异性的抗肿瘤免疫反应。该免疫效应可能与微波消融后肿瘤抗原的大量释放有关。乳腺癌单用免疫治疗效果差,有研究者提出通过联合免疫治疗增强消融免疫效应的方案,但其具体疗效仍需要更多的临床数据支持。随着对于微波消融引起体内免疫效应的研究深入,微波治疗联合免疫检查点抑制剂疗法有望成为全新的精准治疗策略和理念。本文对微波消融在乳腺癌局部精准治疗中的应用研究新进展及未来发展方向进行总结。

关键词: 乳腺癌, 局部治疗, 微波消融, 免疫治疗

Abstract:

Breast cancer is the most common malignant tumor in women. Surgery is the main treatment for early breast cancer. At present, great progress has been made in the diagnosis and treatment of early breast cancer. Howover, innovative approaches are still needed to reduce trauma and improve patients' outcomes. With the progress of innovative research on the treatment of breast cancer, non-surgical treatment of breast and axilla has become a research hotspot of treatment of early breast cancer. Microwave ablation, as a minimally invasive and precise local treatment, has the characteristics of speedy ablation, simple operation method, less postoperative complications and so on. At present, microwave ablation has been used to treat early breast cancer, and has achieved clinical efficacy. In addition, some studies have been reported that microwave ablation of early breast cancer is conducive to regulating the tumor immune microenvironment and stimulating the antigen-specific anti-tumor immune effect in the body. This immune effect may be related to the massive release of tumor antigen after microwave ablation. The effect of immunotherapy alone for breast cancer is poor. Some researchers have proposed a scheme to enhance the ablation immune effect through combined immunotherapy, but its specific effect still needs more clinical data support. With more and more research on the immune effect induced by ablation therapy, microwave ablation combined with immune checkpoint inhibitor is expected to become a new strategy in the precise treatment of breast tumor. This article summarized the new progress and future development direction of microwave ablation in local precise treatment of breast cancer.

Key words: Breast cancer, Local therapy, Microwave ablation, Immunotherapy

中图分类号:

R737.9

周文斌, 谢晖, 丁强, 王水. 在乳腺癌局部精准治疗中的新进展：联合免疫治疗未来可期[J]. 中国癌症杂志, 2022, 32(8): 698-704.

ZHOU Wenbin, XIE Hui, DING Qiang, WANG Shui. New research progress of microwave ablation in the local precise treatment of early-stage breast cancer: the prospect of combined immunotherapy is promising[J]. China Oncology, 2022, 32(8): 698-704.

参考文献 45

[1]	YU M X, PAN H, CHE N, et al. Microwave ablation of primary breast cancer inhibits metastatic progression in model mice via activation of natural killer cells[J]. Cell Mol Immunol, 2021, 18(9): 2153-2164. doi: 10.1038/s41423-020-0449-0
[2]	PHD H S, JACQUES FERLAY MSC M, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA A Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[3]	SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. doi: 10.3322/caac.21708
[4]	FORNAGE B D, HUNT K K. Image-guided percutaneous ablation of small breast cancer: which technique is leading the pack?[J]. Technol Cancer Res Treat, 2015, 14(2): 209-211. doi: 10.7785/tcrt.2012.500395
[5]	CHU K F, DUPUY D E. Thermal ablation of tumours: biological mechanisms and advances in therapy[J]. Nat Rev Cancer, 2014, 14(3): 199-208. doi: 10.1038/nrc3672
[6]	PETROWSKY H, FRITSCH R, GUCKENBERGER M, et al. Modern therapeutic approaches for the treatment of malignant liver tumours[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(12): 755-772. doi: 10.1038/s41575-020-0314-8
[7]	AHMED M, BRACE C L, LEE F T, et al. Principles of and advances in percutaneous ablation[J]. Radiology, 2011, 258(2): 351-369. doi: 10.1148/radiol.10081634
[8]	SIMMONS R M, BALLMAN K V, COX C, et al. A phase Ⅱ trial exploring the success of cryoablation therapy in the treatment of invasive breast carcinoma: results from ACOSOG (alliance) Z1072[J]. Ann Surg Oncol, 2016, 23(8): 2438-2445. doi: 10.1245/s10434-016-5275-3
[9]	CAZZATO R L, DE LARA C T, BUY X, et al. Single-centre experience with percutaneous cryoablation of breast cancer in 23 consecutive non-surgical patients[J]. Cardiovasc Intervent Radiol, 2015, 38(5): 1237-1243. doi: 10.1007/s00270-015-1181-5
[10]	PALUSSIÈRE J, HENRIQUES C, MAURIAC L, et al. Radiofrequency ablation as a substitute for surgery in elderly patients with nonresected breast cancer: pilot study with long-term outcomes[J]. Radiology, 2012, 264(2): 597-605. doi: 10.1148/radiol.12111303
[11]	FINE R E, GILMORE R C, DIETZ J R, et al. Cryoablation without excision for low-risk early-stage breast cancer: 3-year interim analysis of ipsilateral breast tumor recurrence in the ICE3 trial[J]. Ann Surg Oncol, 2021, 28(10): 5525-5534. doi: 10.1245/s10434-021-10501-4
[12]	SIMON C J, DUPUY D E, MAYO-SMITH W W. Microwave ablation: principles and applications[J]. Radiographics, 2005, 25(Suppl 1): S69-S83. doi: 10.1148/rg.25si055501
[13]	ZHOU W B, ZHA X M, LIU X A, et al. US-guided percutaneous microwave coagulation of small breast cancers: a clinical study[J]. Radiology, 2012, 263(2): 364-373. doi: 10.1148/radiol.12111901
[14]	ZHOU W B, LIANG M D, PAN H, et al. Comparison of ablation zones among different tissues using 2 450 MHz cooled-shaft microwave antenna: results in ex vivo porcine models[J]. PLoS One, 2013, 8(8): e71873. doi: 10.1371/journal.pone.0071873
[15]	ZHOU W B, JIANG Y N, CHEN L, et al. Image and pathological changes after microwave ablation of breast cancer: a pilot study[J]. Eur J Radiol, 2014, 83(10): 1771-1777. doi: 10.1016/j.ejrad.2014.06.015
[16]	ZHOU W B, DING Q, LIU X A, et al. Percutaneous microwave coagulation for eradication of VX2 tumors subcutaneously in rabbits[J]. World J Surg Oncol, 2012, 10: 97. doi: 10.1186/1477-7819-10-97
[17]	KONG P, CHEN L, SHI X, et al. Microwave ablation combined with doxorubicin enhances cell death via promoting reactive oxygen species generation in breast cancer cells[J]. Diagn Interv Imaging, 2018, 99(12): 783-791. doi: 10.1016/j.diii.2018.06.004
[18]	KONG P, PAN H, YU M, et al. Insufficient microwave ablation-induced promotion of distant metastasis is suppressed by β-catenin pathway inhibition in breast cancer[J]. Oncotarget, 2017, 8(70): 115089-115101. doi: 10.18632/oncotarget.22859
[19]	SHI X, PAN H, GE H, et al. Subsequent cooling-circulation after radiofrequency and microwave ablation avoids secondary indirect damage induced by residual thermal energy[J]. Diagn Interv Radiol, 2019, 25(4): 291-297. doi: 10.5152/dir.2019.17455
[20]	ZHOU W B, YU M X, PAN H, et al. Microwave ablation induces Th1-type immune response with activation of ICOS pathway in early-stage breast cancer[J]. J Immunother Cancer, 2021, 9(4): e002343. doi: 10.1136/jitc-2021-002343
[21]	TOLBA M F, OMAR H A. Immunotherapy, an evolving approach for the management of triple negative breast cancer: converting non-responders to responders[J]. Crit Rev Oncol Hematol, 2018, 122: 202-207. doi: 10.1016/j.critrevonc.2018.01.005
[22]	EMENS L A. Breast cancer immunotherapy: facts and hopes[J]. Clin Cancer Res, 2018, 24(3): 511-520. doi: 10.1158/1078-0432.CCR-16-3001
[23]	ROBERT C, RIBAS A, SCHACHTER J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study[J]. Lancet Oncol, 2019, 20(9): 1239-1251. doi: 10.1016/S1470-2045(19)30388-2
[24]	ROBERT C, THOMAS L, BONDARENKO I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma[J]. N Engl J Med, 2011, 364(26): 2517-2526. doi: 10.1056/NEJMoa1104621
[25]	SCHMID P, RUGO H S, ADAMS S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21(1): 44-59. doi: 10.1016/S1470-2045(19)30689-8
[26]	EMENS L A, CRUZ C, EDER J P, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase Ⅰ study[J]. JAMA Oncol, 2019, 5(1): 74-82. doi: 10.1001/jamaoncol.2018.4224
[27]	SCHUMACHER T N, SCHREIBER R D. Neoantigens in cancer immunotherapy[J]. Science, 2015, 348(6230): 69-74. doi: 10.1126/science.aaa4971
[28]	MCARTHUR H L, DIAB A, PAGE D B, et al. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling[J]. Clin Cancer Res, 2016, 22(23): 5729-5737. doi: 10.1158/1078-0432.CCR-16-0190
[29]	HO A Y, BARKER C A, ARNOLD B B, et al. A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer[J]. Cancer, 2020, 126(4): 850-860. doi: 10.1002/cncr.32599
[30]	VOORWERK L, SLAGTER M, HORLINGS H M, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial[J]. Nat Med, 2019, 25(6): 920-928. doi: 10.1038/s41591-019-0432-4
[31]	DEMARIA S, GOLDEN E B, FORMENTI S C. Role of local radiation therapy in cancer immunotherapy[J]. JAMA Oncol, 2015, 1(9): 1325-1332. doi: 10.1001/jamaoncol.2015.2756
[32]	BADWE R, HAWALDAR R, NAIR N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial[J]. Lancet Oncol, 2015, 16(13): 1380-1388. doi: 10.1016/S1470-2045(15)00135-7
[33]	ZHAO J, WEN X F, TIAN L, et al. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer[J]. Nat Commun, 2019, 10(1): 899. doi: 10.1038/s41467-019-08782-1
[34]	DEN BROK M H M G M, SUTMULLER R P M, VAN DER VOORT R, et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity[J]. Cancer Res, 2004, 64(11): 4024-4029. doi: 10.1158/0008-5472.CAN-03-3949
[35]	FORMENTI S C, DEMARIA S. Systemic effects of local radiotherapy[J]. Lancet Oncol, 2009, 10(7): 718-726. doi: 10.1016/S1470-2045(09)70082-8
[36]	SÁNCHEZ-ORTIZ R F, TANNIR N, AHRAR K, et al. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine?[J]. J Urol, 2003, 170(1): 178-179. doi: 10.1097/01.ju.0000070823.38336.7b
[37]	KIM H, PARK B K, KIM C K. Spontaneous regression of pulmonary and adrenal metastases following percutaneous radiofrequency ablation of a recurrent renal cell carcinoma[J]. Korean J Radiol, 2008, 9(5): 470-472. doi: 10.3348/kjr.2008.9.5.470
[38]	SOANES W A, ABLIN R J, GONDER M J. Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations[J]. J Urol, 1970, 104(1): 154-159. doi: 10.1016/S0022-5347(17)61690-2
[39]	MCGAHAN J P, BROCK J M, TESLUK H, et al. Hepatic ablation with use of radio-frequency electrocautery in the animal model[J]. J Vasc Interv Radiol, 1992, 3(2): 291-297. doi: 10.1016/S1051-0443(92)72028-4
[40]	LI L, WANG W, PAN H, et al. Microwave ablation combined with OK-432 induces Th1-type response and specific antitumor immunity in a murine model of breast cancer[J]. J Transl Med, 2017, 15(1): 23. doi: 10.1186/s12967-017-1124-9
[41]	ZHU J, YU M, CHEN L, et al. Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: a pre-clinical study in a murine model[J]. Diagn Interv Imaging, 2018, 99(3): 135-142. doi: 10.1016/j.diii.2017.12.011
[42]	ZHOU W B, YU M X, MAO X R, et al. Landscape of the peripheral immune response induced by local microwave ablation in patients with breast cancer[J]. Adv Sci (Weinh), 2022, 9(17): e2200033.
[43]	HAEN S P, GOUTTEFANGEAS C, SCHMIDT D, et al. Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation[J]. Cell Stress Chaperones, 2011, 16(5): 495-504. doi: 10.1007/s12192-011-0261-y
[44]	GU T, GE Y, SONG Y Z, et al. Hepatic radiofrequency ablation causes an increase of circulating histones in patients with hepatocellular carcinoma[J]. Scand J Clin Lab Invest, 2015, 75(7): 621-627. doi: 10.3109/00365513.2015.1050689
[45]	LI G F, STAVELEY-O’CARROLL K F, KIMCHI E T. Potential of radiofrequency ablation in combination with immunotherapy in the treatment of hepatocellular carcinoma[J]. J Clin Trials, 2016, 6(2): 257.

在乳腺癌局部精准治疗中的新进展：联合免疫治疗未来可期

New research progress of microwave ablation in the local precise treatment of early-stage breast cancer: the prospect of combined immunotherapy is promising

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 45

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张景臣, 李新, 李江涛, 李海平, 陈艳丽, 牛冰, 祁川川, 叶贝贝. LINC02163靶向miR-338-3p影响乳腺癌细胞增殖、侵袭及迁移[J]. 中国癌症杂志, 2022, 32(9): 818-826.
[2]	中国抗癌协会乳腺癌专业委员会, 中国医师协会外科医师分会乳腺外科医师委员会, 上海市抗癌协会乳腺癌专业委员会. 乳腺肿瘤整形与乳房重建专家共识（2022年版）[J]. 中国癌症杂志, 2022, 32(9): 836-924.
[3]	肖玉铃, 朱秀之, 江一舟, 邵志敏. 三阴性乳腺癌精准治疗研究的新进展与未来展望[J]. 中国癌症杂志, 2022, 32(8): 669-679.
[4]	邱鹏飞, 王永胜. 前哨淋巴结时代乳腺癌的精准区域处理：演进与展望[J]. 中国癌症杂志, 2022, 32(8): 680-687.
[5]	张羽, 刘强. 液体活检在乳腺癌精准治疗中的应用进展及展望[J]. 中国癌症杂志, 2022, 32(8): 688-697.
[6]	刘燚铭, 范蕾, 莫淼, 邵志敏, 余科达. 卵巢功能抑制治疗雌激素受体阳性早期乳腺癌的短期效应和长期生存的影响因素分析[J]. 中国癌症杂志, 2022, 32(8): 705-711.
[7]	肖佳龙, 莫淼, 周昌明, 王泽洲, 沈洁, 袁晶, 余科达, 柳光宇, 吴炅, 沈镇宙, 邵志敏, 郑莹. 体重指数与年龄交互作用对乳腺癌患者预后影响的研究[J]. 中国癌症杂志, 2022, 32(8): 719-726.
[8]	陈安莉, 沈浩元, 阳仕雄, 邓春燕, 胡超华, 刘汉忠, 王舒, 钱芳. 血浆长链非编码RNA H19对乳腺癌新辅助治疗效果的预测价值[J]. 中国癌症杂志, 2022, 32(8): 727-735.
[9]	刘强, 方仪, 王靖. 单细胞测序技术在乳腺癌研究中的应用进展[J]. 中国癌症杂志, 2022, 32(7): 635-642.
[10]	钱瑶(综述), 刘锋(审校). 乳腺癌新辅助内分泌治疗的研究进展及展望[J]. 中国癌症杂志, 2022, 32(7): 643-649.
[11]	苏春霞, 周彩存. 晚期非小细胞肺癌免疫治疗现状及未来方向[J]. 中国癌症杂志, 2022, 32(6): 478-486.
[12]	虞思来, 倪建佼, 朱正飞. 免疫治疗时代不可手术局部晚期非小细胞肺癌的治疗：现状与展望[J]. 中国癌症杂志, 2022, 32(6): 487-498.
[13]	贾晓青, 孙晓寅, 蒋蓓琦, 梅章懿, 傅韵, 莊志刚. 类泛素化neddylation修饰调控乳腺癌中核纤层蛋白lamin B1的表达[J]. 中国癌症杂志, 2022, 32(6): 535-541.
[14]	刘建兰, 陈黛诗, 胡泓, 周冬仙, 胡锦涛. HER2阳性浸润性乳腺癌新辅助治疗反应的预测因子及治疗前后HER2状态变化的评估[J]. 中国癌症杂志, 2022, 32(5): 417-426.
[15]	章倩, 方晓燕, 刘娟, 刘进, 程蕾蕾, 孙菁. 早期左侧乳腺癌保乳术后大分割放疗同期瘤床加量的安全性及心脏亚结构剂量评估的重要性研究[J]. 中国癌症杂志, 2022, 32(5): 427-435.